0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Attention-deficit/hyperactivity disorder- Market Insight, Epidemiology and Market Forecast - 2028
Published Date: March 2019
|
Report Code: DELV-Mark-329
Home | Market Reports | Health | Health Conditions | Neurological Conditions
Attention deficit hyperactivity disorder Market Insight Epidemiology and Market Forecast 2028

Attention-deficit/hyperactivity disorder- Market Insight, Epidemiology and Market Forecast - 2028

Code: DELV-Mark-329
Report
March 2019
100 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Attention-deficit/hyperactivity disorder (ADHD) epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Attention-deficit/hyperactivity disorder (ADHD) Understanding and Treatment Algorithm
The market report provides the overview of the Attention-deficit/hyperactivity disorder (ADHD) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Attention-deficit/hyperactivity disorder (ADHD) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Attention-deficit/hyperactivity disorder (ADHD) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Attention-deficit/hyperactivity disorder (ADHD) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Attention-deficit/hyperactivity disorder (ADHD) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Attention-deficit/hyperactivity disorder (ADHD) market.

Attention-deficit/hyperactivity disorder (ADHD) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Attention-deficit/hyperactivity disorder (ADHD) Report Insights
• Patient Population in Attention-deficit/hyperactivity disorder (ADHD)
• Therapeutic Approaches in Attention-deficit/hyperactivity disorder (ADHD)
• Attention-deficit/hyperactivity disorder (ADHD) Pipeline Analysis
• Attention-deficit/hyperactivity disorder (ADHD) Market Size and Trends
• Attention-deficit/hyperactivity disorder (ADHD) Market Opportunities
• Impact of upcoming Therapies in Attention-deficit/hyperactivity disorder (ADHD)

Attention-deficit/hyperactivity disorder (ADHD) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Attention-deficit/hyperactivity disorder (ADHD) Report Assessment
• Current Treatment Practices in Attention-deficit/hyperactivity disorder (ADHD)
• Unmet Needs in Attention-deficit/hyperactivity disorder (ADHD)
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Attention-deficit/hyperactivity disorder (ADHD) market
• Organize sales and marketing efforts by identifying the best opportunities for Attention-deficit/hyperactivity disorder (ADHD) market
• To understand the future market competition in the Attention-deficit/hyperactivity disorder (ADHD) market.

1. Report Introduction
2. Attention-deficit/hyperactivity disorder (ADHD) Market Overview at a Glance
2.1. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2016
2.2. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2028
3. Disease Background and Overview: Attention-deficit/hyperactivity disorder (ADHD)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM
4.3. Total Prevalent Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM – By Countries
5. Epidemiology of Attention-deficit/hyperactivity disorder (ADHD) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.1.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.1.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.1.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.1.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.4.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.4.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.4.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.4.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.5.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.5.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.6.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.6.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.7.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.7.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.8.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.8.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.9.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.9.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Attention-deficit/hyperactivity disorder (ADHD)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Attention-deficit/hyperactivity disorder (ADHD)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Attention-deficit/hyperactivity disorder (ADHD) : 7MM Market Analysis
12.1. 7MM Market Size of Attention-deficit/hyperactivity disorder (ADHD)
12.2. 7MM Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD)
12.3. 7MM Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products
13. Attention-deficit/hyperactivity disorder (ADHD) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United States
13.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United States
13.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Germany
13.2.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Germany
13.2.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in France
13.2.2.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in France
13.2.2.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Italy
13.2.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Italy
13.2.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Spain
13.2.4.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Spain
13.2.4.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom
13.2.5.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Japan
13.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Japan
13.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

LIST OF TABLES :

Table 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Table 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)

LIST OF FIGURES :

Figure 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
Figure 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$6250
This license allows only one user to access the PDF.

Electronic (PDF)
$12500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$18750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Seventh Sense AI

RELATED REPORTS

Global and United States Levodopa Market Insights Forecast to 2027
Global and United States Levodopa Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-15B7475
Sat Nov 20 00:00:00 UTC 2021

Add to Cart

Global and China Neurosurgical Operating Room Table Market Insights Forecast to 2027
Global and China Neurosurgical Operating Room Table Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-10H7225
Tue Nov 02 00:00:00 UTC 2021

Add to Cart

Global and China Deep Brain Stimulation System Market Insights Forecast to 2027
Global and China Deep Brain Stimulation System Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-10Z6921
Mon Oct 25 00:00:00 UTC 2021

Add to Cart

China Autism Spectrum Disorder Diagnosis and Therapeutics Market Report Forecast 2021 2027
China Autism Spectrum Disorder Diagnosis and Therapeutics Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-6U7133
Sat Oct 02 00:00:00 UTC 2021

Add to Cart